ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $72.80, for a total value of $207,480.00. Following the transaction, the chief financial officer owned 171,843 shares of the company’s stock, valued at approximately $12,510,170.40. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 1.8%

ANI Pharmaceuticals stock opened at $71.92 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The company has a 50-day simple moving average of $79.31 and a 200-day simple moving average of $78.56. The firm has a market capitalization of $1.65 billion, a P/E ratio of 15.50 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the business earned $1.80 earnings per share. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Corient Private Wealth LP increased its position in ANI Pharmaceuticals by 95.2% during the second quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company’s stock worth $1,995,000 after buying an additional 11,754 shares during the last quarter. Amundi increased its position in ANI Pharmaceuticals by 595.5% in the 2nd quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company’s stock worth $2,632,000 after buying an additional 27,222 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in ANI Pharmaceuticals during the second quarter worth $1,449,000. California State Teachers Retirement System increased its holdings in shares of ANI Pharmaceuticals by 7,977.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock worth $164,200,000 after purchasing an additional 1,959,017 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $724,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.